Loading
Boundless Bio, Inc. Stock: price and insider trades · United States
US·Mcap US$56.2M
1 insider bought €10k of shares over the last 90 days, the latest filed 21 Jul 2026.
Boundless Bio, Inc.: what insiders have been doing
Boundless Bio, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 26 filings came from 3 insiders.
Open-market activity splits into 22 purchases totalling €465k and 2 sales totalling €82k; 1 insider sit on the buying side and 2 insiders on the selling side. The totals do not cover 10 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 major shareholder among the declarants. One trade stands out by size: a purchase of €102k from Tang Kevin, disclosed on 13 July 2026, or 0.19% of market capitalisation.
With 26 filings in twelve months, the company is more active than the median of 19 filings across the 5,808 companies we follow on the same exchange. Since 2024, the database holds 22 purchases and 2 sales by insiders of the company.
The clock since the last published purchase (21 July 2026) now reads 89 days. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€465,281
22 ops. · all time
Sell Volume
€81,572
2 ops. · all time
Who traded when
BuySaleKevin Tang22 buys1 sale
ARCH Venture Fund IX, L.P.1 sale
Keith Crandell1 sale
Since the insiders bought
- -5.2%Entry US$2.52 · Close 14 Oct 2026 US$2.39
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.43
Analyst consensus
1 analysts3.00/5
US$4.00Target US$4.00(+65%)US$4.00
Income statement
EBITDA-US$62.3M
Net income-US$58.2M0.0% margin
Valuation
PER (forward)-2.5x
P/Book0.8x
Beta0.47
Balance sheet & cash
Market capUS$56.2M
Total debtUS$49M
Free Cash Flow-US$47.2M
Debt / Equity56%
Profitability & ownership
ROE-67.9%
ROA-32.8%
% insiders12.5%
% institutions67.3%
Last declaration on 28 August 2026
Declarations33 total
18,300 shares@ US$2.970.088% mcap9.1% of flowCommon StockSEC:0001178579-26-000018:0
2,975 shares@ US$2.440.012% mcap1.2% of flowCommon StockSEC:0001178579-26-000017:2
Canonical exit: 19 Oct 2026 (T+90)
265 shares@ US$2.440.0011% mcap0.1% of flowCommon StockSEC:0001178579-26-000017:0
Canonical exit: 15 Oct 2026 (T+90)
1,623 shares@ US$2.440.0065% mcap0.7% of flowCommon StockSEC:0001178579-26-000017:1
Canonical exit: 18 Oct 2026 (T+90)
43,878 shares@ US$2.430.18% mcap18.3% of flowCommon StockSEC:0001178579-26-000015:0
Canonical exit: 12 Oct 2026 (T+90)
1,600 shares@ US$2.440.0064% mcap0.7% of flowCommon StockSEC:0001178579-26-000015:1
Canonical exit: 13 Oct 2026 (T+90)
18,491 shares@ US$2.440.074% mcap7.7% of flowCommon StockSEC:0001178579-26-000015:2
Canonical exit: 14 Oct 2026 (T+90)
7 shares@ US$2.480.0000% mcap0.0% of flowCommon StockSEC:0001178579-26-000011:0
Canonical exit: 7 Oct 2026 (T+90)
43,367 shares@ US$2.430.17% mcap18.0% of flowCommon StockSEC:0001178579-26-000011:1
Canonical exit: 8 Oct 2026 (T+90)
48,211 shares@ US$2.420.19% mcap20.0% of flowCommon StockSEC:0001178579-26-000011:2
Canonical exit: 11 Oct 2026 (T+90)
27,062 shares@ US$2.490.11% mcap11.5% of flowCommon StockSEC:0001178579-26-000010:0
Canonical exit: 4 Oct 2026 (T+90)
15,810 shares@ US$2.480.064% mcap6.7% of flowCommon StockSEC:0001178579-26-000010:1
Canonical exit: 5 Oct 2026 (T+90)
14,338 shares@ US$2.460.058% mcap6.0% of flowCommon StockSEC:0001178579-26-000010:2
Canonical exit: 6 Oct 2026 (T+90)
16,000 shares@ US$1.030.027% mcap29.3% of flowCommon StockSEC:0001012975-26-000621:0
16,000 shares@ US$2.490.066% mcap70.7% of flowCommon StockSEC:0001012975-26-000621:1
16,000 shares@ US$1.030.027% mcap29.3% of flowCommon StockSEC:0001012975-26-000622:0
▼
Same trade as the filing by ARCH Venture Fund IX, L.P., counted once · View ↗
16,000 shares@ US$2.490.066% mcap70.7% of flowCommon StockSEC:0001012975-26-000622:1
25,930 sharesCommon StockSEC:0001178579-26-000009:0
Canonical exit: 28 Sept 2026 (T+90)
100 sharesCommon StockSEC:0001178579-26-000009:1
Canonical exit: 28 Sept 2026 (T+90)
71,612 sharesCommon StockSEC:0001178579-26-000009:2
Canonical exit: 29 Sept 2026 (T+90)
9,821 sharesCommon StockSEC:0001178579-26-000009:3
Canonical exit: 30 Sept 2026 (T+90)
145,880 sharesCommon StockSEC:0001178579-26-000008:0
Canonical exit: 23 Sept 2026 (T+90)
510 sharesCommon StockSEC:0001178579-26-000008:1
Canonical exit: 23 Sept 2026 (T+90)
75,047 sharesCommon StockSEC:0001178579-26-000008:2
Canonical exit: 24 Sept 2026 (T+90)
134 sharesCommon StockSEC:0001178579-26-000008:3
Canonical exit: 24 Sept 2026 (T+90)
25 of 33 declarations
About Boundless Bio, Inc.
Boundless Bio, Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer using advanced technologies. It is listed on NASDAQ under the ticker symbol XNAS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
